logo
  • SELECT LICENSE :

  • US $4,299.00
  • US $8,599.00

Radiopharmaceutical Market, By Type (Diagnostic and Therapeutic), By Application (Oncology, Cardiology) opportunities and forecast 2020-2027

  • DLR2183
  • 20 September, 2020
  • Pharma & Healthcare
  • Pages: 120
  • Global
Market Overview

Growth in nuclear medicine market can principally be attributed to the factors such as the growing prevalence and incidences of cardiac ailments and cancer and also to the initiatives taken to lessen demand-supply gap of the Mo-99.

Growing inclination of the disease targeted cancer therapy, growing patient consciousness levels demanding precise diagnosis and growing applications of the molecular imaging are some of major drivers of global radiopharmaceuticals market. Technological developments enabling use of monoclonal antibodies and radio-labeled peptides for the treatment and diagnosis of cancerous tumors will fuel future growth in the market.

Segment Overview

Based on type, the market is categorized into therapeutic and diagnostic medicine. The therapeutic segment is further segmented into beta emitter, alpha emitters, and brachytherapy isotopes. In 2013, FDA approved the very first and only product for the alpha emitters in market, launched by the giant Bayer AG under the name of Xofigo. The North America region for Ra-223 is anticipated to command largest share due to the targeted properties over the beta emitters and also due to being the only alpha-emitter invention available in the market.

Based on application, market is segmented into PET, SPECT, and therapeutic applications. The SPECT applications is categorized into bone scans, pulmonary scans, thyroid applications, cardiology, and other SPECT applications. The thyroid segment is expected to register highest growth rate over the forecast period. The high growth rate of the segment can be accredited to the growing prevalence and incidence of thyroid disorders.

Regional Overview

The global market has been segmented on the basis of four major segments as, North America, the Asia Pacific, Europe, Latin America Middle East and Africa. In 2019, North America is expected to command the largest share of the market. The large share is attributed to development of the novel technologies for the production of radioisotopes, company initiatives and government funding, in the region.

Competitor overview

Stakeholders operating in current radiopharmaceutical market are prerequisite to comply with published FDA guidelines throughout drug development phase. In August 2019, U.S. FDA published Oncology Therapeutic Radiopharmaceuticals (OTR): Nonclinical Studies and also the Labelling Recommendations. Large chunk of the companies operating in current radiopharmaceutical market has mostly been active participants in diagnostic sector, fulfilling the stringent supervisory guidelines is primary area of focus. Currently, participants in the market are expected to work in aggregation with companies active in traditional pharmaceutical space to confirm that the commercialization and drug development approaches align with FDA guidelines. Some major points included by FDA focus on evaluation of toxicities from the ligand, radiation toxicities, and the data pertaining to product labelling, among others. Stakeholders in the market will continue their search of achieving approval from FDA to stay relevant in current market landscape.

However over the past few years, FDA has approved almost three radical radiopharmaceutical therapies including Radium-223, or MIBG for paraganglioma, LuDOTATATE for neuroendocrine carcinomas, and pheochromocytoma.

Key Players
  1. Cardinal Health
  2. GE Healthcare
  3. Curium
  4. Lantheus Medical Imaging
  5. Bayer AG
  6. Bracco Imaging
  7. Eczacýbaþý-Monrol Nuclear Products
  8. Nordion
  9. Advanced Accelerator Applications
  10. NTP Radioisotopes

Market Segmentation

By Type
  • Diagnostic Nuclear Medicine
    • SPECT Radiopharmaceuticals
    • Technetium-99m
    • Thallium-201
    • Gallium-67
    • Iodine-123
    • Other SPECT Isotopes
    • PET Radiopharmaceuticals
    • F-18
    • Ru-82
    • Other PET Isotopes
  • Therapeutic Nuclear Medicine
    • Alpha Emitters
    • Ra-223
    • Beta Emitters
    • Iodine-131
    • Yttrium-90
    • Samarium-153
    • Lutetium-177
    • Rhenium-186
    • Other Beta Emitters
    • Brachytherapy Isotopes
    • Iodine-125
    • Palladium-103
    • Cesium-131
    • Iridium-192
    • Other Brachytherapy Isotopes
By Application
  • Diagnostic Applications
    • SPECT Applications
    • Cardiology
    • Bone Scans
    • Thyroid Applications
    • Pulmonary Scans
    • Other SPECT Applications
    • PET Applications
    • Oncology
    • Cardiology
    • Neurology
    • Other PET Applications
  • Therapeutic Applications
    • Thyroid Indications
    • Bone Metastasis
    • Lymphoma
    • Endocrine Tumors
    • Other Indications
By Geography
  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • UAE
    • Rest of LAMEA


1 EXECUTIVE SUMMARY 15

    2 MARKET INTRODUCTION 16

    • 2.1 DEFINITION 16
    • 2.2 SCOPE OF THE STUDY 16
    • 2.3 RESEARCH OBJECTIVE 16
    • 2.4 MARKET STRUCTURE 16

    3 RESEARCH METHODOLOGY 17

    • 3.1 RESEARCH PROCESS 17
    • 3.2 PRIMARY RESEARCH 18
    • 3.3 SECONDARY RESEARCH 19
    • 3.4 MARKET SIZE ESTIMATION 20
    • 3.5 FORECAST MODEL 21
    • 3.6 LIST OF ASSUMPTIONS 22

    4 MARKET DYNAMICS 23

    • 4.1 OVERVIEW 23
    • 4.2 DRIVERS 24
      • 4.2.1 GROWING APPLICATION OF RADIOISOTOPES IN THE HEALTHCARE INDUSTRY 24
      • 4.2.2 INCREASING USE OF RADIOPHARMACEUTICALS FOR THE DIAGNOSIS & TREATMENT OF CHRONIC DISEASES 24
      • 4.2.3 TECHNOLOGICAL ADVANCEMENTS IN DIAGNOSTICS SECTOR 24
      • 4.2.4 DRIVERS ANALYSIS 25
    • 4.3 RESTRAINTS 26
      • 4.3.1 SHORT HALF-LIFE OF RADIOPHARMACEUTICALS 26
      • 4.3.2 HIGH COST OF RADIOPHARMACEUTICALS 26
      • 4.3.3 RESTRAINTS ANALYSIS 26
    • 4.4 OPPORTUNITY 27
      • 4.4.1 TECHNOLOGICAL ADVANCEMENTS IN RADIOPHARMACEUTICAL OR MEDICINAL RADIOCOMPOUNDS 27

    5 MARKET FACTOR ANALYSIS 28

    • 5.1 VALUE CHAIN ANALYSIS 28
      • 5.1.1 R&D 29
      • 5.1.2 MANUFACTURING 29
      • 5.1.3 DISTRIBUTION & SALES 29
      • 5.1.4 POST-SALES MONITORING 29
    • 5.2 PORTER’S FIVE FORCES MODEL 30
      • 5.2.1 THREAT OF NEW ENTRANTS 31
      • 5.2.2 BARGAINING POWER OF SUPPLIERS 31
      • 5.2.3 BARGAINING POWER OF BUYERS 31
      • 5.2.4 THREAT OF SUBSTITUTES 31
      • 5.2.5 INTENSITY OF RIVALRY 31
    • 5.3 NUMBER OF PROCEDURES USING MEDICAL ISOTOPES WORLDWIDE IN 2018 32

    6 GLOBAL RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE 33

    • 6.1 OVERVIEW 33
    • 6.2 DIAGNOSTICS 36
    • 6.3 THERAPEUTICS 36

    7 GLOBAL RADIOPHARMACEUTICALS MARKET, BY APPLICATION 37

    • 7.1 OVERVIEW 37
    • 7.2 NEUROLOGY 38
    • 7.3 CARDIOLOGY 39
    • 7.4 ONCOLOGY 39
    • 7.5 ENDOCRINOLOGY 39

    8 GLOBAL RADIOPHARMACEUTICALS MARKET, BY END USER 40

    • 8.1 OVERVIEWS 40
    • 8.2 HOSPITALS & CLINICS 41
    • 8.3 DIAGNOSTIC CENTRES 41
    • 8.4 ACADEMIC & RESEARCH INSTITUTIONS 41

    9 GLOBAL RADIOPHARMACEUTICALS MARKET, BY REGION 42

    • 9.1 OVERVIEWS 42
    • 9.2 AMERICAS 44
      • 9.2.1 NORTH AMERICA 46
        • 9.2.1.1 US 49
        • 9.2.1.2 CANADA 51
      • 9.2.2 LATIN AMERICA 53
        • 9.2.2.1 MEXICO 55
        • 9.2.2.2 BRAZIL 57
        • 9.2.2.3 REST OF LATIN AMERICA 59
  • 9.3 EUROPE 61
    • 9.3.1 WESTERN EUROPE 63
      • 9.3.1.1 GERMANY 66
      • 9.3.1.2 FRANCE 68
      • 9.3.1.3 UK 70
      • 9.3.1.4 ITALY 72
      • 9.3.1.5 SPAIN 74
      • 9.3.1.6 SCANDINAVIA 76
      • 9.3.1.7 REST OF WESTERN EUROPE 78
    • 9.3.2 EASTERN EUROPE 80
  • 9.4 ASIA-PACIFIC 82
    • 9.4.1 CHINA 84
    • 9.4.2 INDIA 86
    • 9.4.3 JAPAN 87
    • 9.4.4 AUSTRALIA 89
    • 9.4.5 SOUTH KOREA 91
    • 9.4.6 REST OF ASIA-PACIFIC 93
  • 9.5 MIDDLE EAST & AFRICA 95
    • 9.5.1 GCC COUNTRIES 97
    • 9.5.2 SOUTH AFRICA 99
    • 9.5.3 REST OF THE MIDDLE EAST & AFRICA 101
  • 10 COMPETITIVE LANDSCAPE 103

    • 10.1 OVERVIEW 103
    • 10.2 KEY DEVELOPMENTS 104

    11 COMPANY PROFILE 106

    • 11.1 BAYER AG 106
      • 11.1.1 COMPANY OVERVIEW 106
      • 11.1.2 FINANCIAL OVERVIEW 106
      • 11.1.3 PRODUCTS/SERVICES OFFERED 107
      • 11.1.4 KEY DEVELOPMENTS 107
      • 11.1.5 SWOT ANALYSIS 107
      • 11.1.6 KEY STRATEGIES 108
    • 11.2 GE HEALTHCARE 109
      • 11.2.1 COMPANY OVERVIEW 109
      • 11.2.2 FINANCIAL OVERVIEW 109
      • 11.2.3 PRODUCTS/SERVICES OFFERED 110
      • 11.2.4 GE HEALTHCARE: KEY DEVELOPMENTS 110
      • 11.2.5 SWOT ANALYSIS 110
      • 11.2.6 KEY STRATEGIES 111
    • 11.3 BRACCO DIAGNOSTIC INC. 112
      • 11.3.1 COMPANY OVERVIEW 112
      • 11.3.2 FINANCIAL OVERVIEW 112
      • 11.3.3 PRODUCTS/SERVICES OFFERED 112
      • 11.3.4 KEY DEVELOPMENTS 112
      • 11.3.5 SWOT ANALYSIS 113
      • 11.3.6 KEY STRATEGIES 113
    • 11.4 LANTHEUS MEDICAL IMAGING, INC. 114
      • 11.4.1 COMPANY OVERVIEW 114
      • 11.4.2 FINANCIAL OVERVIEW 115
      • 11.4.3 PRODUCTS/SERVICES OFFERED 116
      • 11.4.4 KEY DEVELOPMENTS 116
      • 11.4.5 SWOT ANALYSIS 116
      • 11.4.6 KEY STRATEGIES 116
    • 11.5 CARDINAL HEALTH 117
      • 11.5.1 COMPANY OVERVIEW 117
      • 11.5.2 FINANCIAL OVERVIEW 117
      • 11.5.3 PRODUCTS/SERVICES OFFERED 118
      • 11.5.4 KEY DEVELOPMENTS 118
      • 11.5.5 SWOT ANALYSIS 118
      • 11.5.6 KEY STRATEGIES 118
    • 11.6 CURIUM 119
      • 11.6.1 COMPANY OVERVIEW 119
      • 11.6.2 FINANCIAL OVERVIEW 119
      • 11.6.3 PRODUCTS/SERVICES OFFERED 119
      • 11.6.4 KEY DEVELOPMENTS 119
      • 11.6.5 SWOT ANALYSIS 120
      • 11.6.6 KEY STRATEGIES 120
    • 11.7 NOVARTIS AG 121
      • 11.7.1 COMPANY OVERVIEW 121
      • 11.7.2 FINANCIAL OVERVIEW 121
      • 11.7.3 PRODUCTS/SERVICES OFFERED 122
      • 11.7.4 KEY DEVELOPMENTS 122
      • 11.7.5 SWOT ANALYSIS 122
      • 11.7.6 KEY STRATEGIES 123
    • 11.8 BWX TECHNOLOGIES, INC. 124
      • 11.8.1 COMPANY OVERVIEW 124
      • 11.8.2 FINANCIAL OVERVIEW 124
      • 11.8.3 PRODUCTS/SERVICES OFFERED 125
      • 11.8.4 KEY DEVELOPMENTS 125
      • 11.8.5 SWOT ANALYSIS 125
      • 11.8.6 KEY STRATEGIES 125
    • 11.9 SIEMENS HEALTHINEERS 126
      • 11.9.1 COMPANY OVERVIEW 126
      • 11.9.2 FINANCIAL OVERVIEW 127
      • 11.9.3 PRODUCTS/SERVICES OFFERED 128
      • 11.9.4 KEY DEVELOPMENTS 128
      • 11.9.5 SWOT ANALYSIS 128
      • 11.9.6 KEY STRATEGIES 129
    • 11.10 JUBILANT LIFE SCIENCES LTD 130
      • 11.10.1 COMPANY OVERVIEW 130
      • 11.10.2 FINANCIAL OVERVIEW 130
      • 11.10.3 PRODUCTS/SERVICES OFFERED 131
      • 11.10.4 KEY DEVELOPMENTS 131
      • 11.10.5 SWOT ANALYSIS 131
      • 11.10.6 KEY STRATEGIES 132

    12 APPENDIX 133

    • 12.1 REFERENCES 133
    • 12.2 RELATED REPORTS 133

    Report You Might be Interested